Praxis Precision Medicines announces Nasdaq Rule 5635(c)(4) inducement grants
Praxis Precision Medicines said its Board Compensation Committee approved inducement grants under Nasdaq Listing Rule 5635(c)(4) on September 1, 2026.
BOSTON, Sept.
03, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc.
NASDAQ:PRAX, a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced that on September 1, 2026, the Compensation Committee of Praxis’ Board of Directors gra…